Navigation Links
VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
Date:4/16/2009

First Selective TLR8 Agonist to Advance for Treatment of Allergy

SAN DIEGO, April 16 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and inflammatory diseases, announced today that it has initiated a Phase I clinical trial of VTX-1463, a selective intranasal TLR8 agonist for the treatment of allergic rhinitis. The objectives of this trial will be to assess safety, tolerability and pharmacokinetics of single and multiple ascending doses of VTX-1463 in approximately 30 healthy volunteers. The trial is being conducted in the Netherlands.

"We are pleased to advance VTX-1463 into the clinic," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx. "This is another milestone for our TLR8 effort as this is the second clinical program initiated in the last six months." VTX-2337 began Phase I clinical trials in cancer patients in November 2008.

VTX-1463 is a small molecule TLR8 agonist that is being developed as a stand-alone agent for the treatment of allergic rhinitis. In preclinical animal studies, this compound has been shown experimentally to dramatically reduce allergic responses without requiring the concomitant administration of allergen. As such, it represents a potential prophylactic and/or therapeutic solution for allergic diseases, regardless of the antigen responsible for the allergic response. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-1463 in healthy volunteers and will help define the appropriate dose(s) for a proof of concept clinical study in allergic patients later this year.

"VTX-1463 is the first selective TLR8 compound to reach the clinic for allergy," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "Aller
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
3. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
4. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
5. Strativa Pharmaceuticals Provides Product Pipeline Update
6. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
7. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
8. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... million advance from Hercules Technology Growth Capital, Inc. (NYSE: ... second and final advance under the Loan and Security ... Kingdom , Alimera Sciences Limited, entered into with ...
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... launches integrated, multi-channel offerings for three fast-growing export sectors -- HONG KONG, Oct. 26 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
... Oct. 25 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended September 30, 2010, on Monday, November 1, ... will host a conference call and webcast on Monday, ... discuss the Company,s third quarter results and corporate developments. ...
Cached Medicine Technology:Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 2Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 3Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 4Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 5Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 6Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 7Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 8Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 9Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 2Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 3
(Date:9/30/2014)... 2014 A new study of ... the impact of stress on metabolism after eating a high-fat ... from a fast food restaurant, about 930 calories and 60 ... 20 minutes every hour for 7 hours, conducting the study ... who had experienced a stressful event in their lives during ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 With ... viral strains emerging every day, it’s a perfect ... The EnviroShield system is an electro-static disinfectant ... applications to surface normally missed with spray-on disinfectant ... nozzle that adds an electrostatic negative charge to ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... WASHINGTON, Feb. 5 Following is a statement,by Daniel ... his last budget, the president had an opportunity to ... nation,s No. 1 killer,and costliest disease. Instead, his proposal ... cure. We,re making steady progress in combating heart,disease and ...
... precisely which bugs in the gut are involved in which ... bugs living in seven members of the same Chinese family. ... and trillions live symbiotically inside the human body. Different people ... them. , The makeup of each persons gut microflora ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today ... Executive Officer, and William Federici, Chief,Financial Officer, will be ... 3:00 p.m. on February 11, 2008 in New York ... will be posted on the,investor link of the Company,s ...
... Compliance Corp. (OTC,Bulletin Board: SCOM) ("Sharps" or the ... small quantity generators of medical,waste, today announced that ... Officer, will present at the RedChip Small-Cap Investor,Conference ... approximately,10:10 a.m. MST (12:10 p.m. EST) on Thursday, ...
... LAKE FOREST, Ill., Feb. 5 BIOSAFE Laboratories, ... and Glycemion, the,United States distributor, have announced the ... use in schools to help identify diabetic and,pre-diabetic ... a two-part process comprised of an immediate fasting ...
... Rapid Growth, WAYNE, Pa., Feb. 5 ... communications,platform specifically designed for the biomedical research community,announced ... of myBW (or myBioWizard), a,unique personalization tool available ... now provides biomedical researchers access to approximately,half a ...
Cached Medicine News:Health News:Statement by Daniel W. Jones, M.D., American Heart Association President on President Bush's FY 2009 Budget Proposal 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 3Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona 2Health News:BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessment Kits to U.S. School Children 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 3
... Two Large Working Channels; 33 cm Working ... is the smallest ureteroscope with two large ... The ACMI MICRO-6 Ureteroscope reduces patient trauma ... or no dilation or general anesthesia. It ...
Smooth, contoured visual obturator provides less traumatic insertion through the urethra and into the bladder....
Semi-Rigid Ureteroscope...
... features a tip diameter of only ... up/down angulation range of 180 for ... areas.,For improved observation, a new optical ... reusable 11.7Fr (3.9mm) sheath dilator, 0.035" ...
Medicine Products: